4712 terminated. 4712 Phase 2, 1154 Phase 1, 117 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4712 | Terminated 4712 |
| Phase 1 | 1154 | Terminated 1154 |
| Phase 3 | 117 | Terminated 117 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Immune Effectors Against Ovarian Cancer OC-CTLs - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| GD2/CD56 Bi-specific CAR-T Cell Therapy bi-4SCAR GD2/CD56 T cells - Malignant Disease | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 60 | 2026-06-01 | 2026-11-02 |
| Engineered Immune Effectors Against Cervical Cancer CC-EIEs - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-03 |
| Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis Antigen-specific T cells CART/CTL and DCvac - Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-02 |
| Intervention of CAR-T Against Cervical Cancer Cervical cancer-specific CAR-T cells - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy bi-4SCAR PSMA/CD70 T cells - Cancer Disease | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 60 | 2026-06-01 | 2026-11-03 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients Semiconductor embedded headband, Sham Headband - Breast Cancer, Gynecologic Cancer | Phase 2 | Terminated | University of Utah | 7 | 2025-11-07 | 2026-08-17 |
| Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin) - Lung Cancer, Non-Small Cell | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 2 | 2025-10-10 | 2026-09-03 |
| NG2 and DLL3 CAR-T Cells Targeting Melanoma NG2 and DLL3 CAR-T cells - Melanoma | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-09-01 | 2026-11-03 |
| Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) Gemcitabine, Cisplatin, Cemiplimab - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 2 | Terminated | Columbia University | 1 | 2025-08-14 | 2026-11-03 |
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) Acasunlimab, Pembrolizumab - Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) | Phase 2 | Terminated | Genmab | 1 | 2025-07-25 | 2026-09-30 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells Engineered Immune Cells - Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-07-01 | 2026-11-03 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer PD-1 vaccine IMU-201 (PD1-Vaxx) - Colorectal Cancer | Phase 2 | Terminated | University of Southampton | 3 | 2025-06-16 | 2026-06-24 |
Showing 20 of 4712. Sign in to see all of them.
Breast Neoplasms (539) · Carcinoma, Non-Small-Cell Lung (434) · Prostatic Neoplasms (281) · Neoplasm Metastasis (273) · Melanoma (260) · Multiple Myeloma (247) · Leukemia, Myeloid, Acute (239) · Colorectal Neoplasms (231) · Lung Neoplasms (192) · Ovarian Neoplasms (188) · Recurrence (186) · Leukemia (184) · Lymphoma (182) · Pancreatic Neoplasms (173)
Neoplasms by Site (3139) · Neoplasms by Histologic Type (2499) · Hemic and Lymphatic Diseases (1187) · Neoplasms, Glandular and Epithelial (987) · Immune System Diseases (876) · Skin and Connective Tissue Diseases (870) · Skin Diseases (863) · Immunoproliferative Disorders (854) · Hematologic Diseases (846) · Lymphoproliferative Disorders (843) · Urogenital Diseases (841) · Urogenital Neoplasms (805) · Pathological Conditions, Signs and Symptoms (787) · Digestive System Diseases (778)
Cyclophosphamide (228) · pembrolizumab (209) · Carboplatin (204) · Cisplatin (193) · Gemcitabine (192) · Bevacizumab (182) · Docetaxel (175) · Paclitaxel (174) · Radiotherapy (165) · Capecitabine (150) · Rituximab (147) · Nivolumab (137) · Fluorouracil (126) · Dexamethasone (125) · Oxaliplatin (124)
National Cancer Institute (NCI) (245) · M.D. Anderson Cancer Center (209) · Novartis Pharmaceuticals (58) · Washington University School of Medicine (52) · Dana-Farber Cancer Institute (51) · Hoffmann-La Roche (46) · Pfizer (46) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (46) · H. Lee Moffitt Cancer Center and Research Institute (39) · Burzynski Research Institute (38) · Bristol-Myers Squibb (37) · Masonic Cancer Center, University of Minnesota (37) · Mayo Clinic (37) · Roswell Park Cancer Institute (37) · University of Washington (36)
United States (3420) · France (419) · Spain (368) · Germany (321) · Italy (312) · Canada (308) · United Kingdom (285) · Belgium (220) · Australia (194) · China (184) · South Korea (177) · Netherlands (146) · Poland (124) · Taiwan (115) · Japan (87)
Stanislaw R. Burzynski, MD, PhD (37) · Steven A Rosenberg, M.D. (16)
PMID 35622074, PMID 31401903, PMID 34398557, PMID 37185961, PMID 39462179, PMID 40812353, PMID 41671463, PMID 20375404, PMID 22682017, PMID 26472751, PMID 28712102, PMID 28835440, PMID 30885996, PMID 31527168, PMID 32379297, PMID 32897402, PMID 33166722, PMID 33720067, PMID 35226739, PMID 35387488, PMID 35844029, PMID 38335473, PMID 39034053, PMID 39077906, PMID 39863139, PMID 42836590, PMID 11224527, PMID 11255275, PMID 11352955, PMID 11441933, PMID 11600601, PMID 12011122, PMID 12011123, PMID 12051882, PMID 12149300, PMID 12586591, PMID 12586807, PMID 12652460, PMID 12694653, PMID 12713990, PMID 12749708, PMID 12771730, PMID 12826431, PMID 12860938, PMID 12944571, PMID 13688369, PMID 14520092, PMID 14534883, PMID 14615449, PMID 14766260
2018 (46), 2017 (44), 2016 (39), 2019 (38), 2009 (35), 2023 (31), P30CA015704 (29), 2014 (28), 2015 (28), P30CA016672 (27), U10CA032102 (26), P30CA072720 (24), P30CA015083 (20), 2008 (18), U10CA021115 (17)